What other stocks do shareholders of ViroPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViroPharma investors own include Caterpillar (CAT) , Johnson & Johnson (JNJ) , Pharmacyclics (PCYC) , Boeing (BA) , Bank of America (BAC) , BioMarin Pharmaceutical (BMRN) , Bristol-Myers Squibb (BMY) , Costco Wholesale (COST) and Deere & Company (DE) .

NASDAQ:VPHM

ViroPharma (VPHM) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free VPHM Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get ViroPharma alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About ViroPharma Stock (NASDAQ:VPHM)

ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

Find out more here >>>

VPHM Stock News Headlines

September 2, 2023 | thestreet.com

HAE: Biotech's Latest Orphan-Drug Race

August 24, 2023 | thetimes.co.uk

Driven out of Eden, from Paradise Lost by John Milton (1608 74)

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2023 | thestreet.com

ViroPharma Stock Hits New 52-Week High (VPHM)

May 2, 2022 | thestreet.com

Market Preview: A Huge Mistake

April 30, 2022 | fool.com

No Swelling Sales Here

January 18, 2022 | thestreet.com

Despite Nasdaq's Record, Market Players Eye Trends Uneasily

See More Headlines

Receive VPHM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ViroPharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:VPHM
CUSIP: 92824110
CIK: 946840
Web: www.viropharma.com
Phone: +1-610-4587300
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

VPHM Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of ViroPharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ViroPharma investors own include Caterpillar (CAT), Johnson & Johnson (JNJ), Pharmacyclics (PCYC), Boeing (BA), Bank of America (BAC), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Costco Wholesale (COST) and Deere & Company (DE).

This page (NASDAQ:VPHM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ViroPharma (VPHM) Stock Price, News & Analysis

About ViroPharma Stock (NASDAQ:VPHM)

VPHM Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

VPHM Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info